Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$26.8 million.

  • Northwest Biotherapeutics' Profit After Tax fell 3847.94% to -$26.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.8 million, marking a year-over-year decrease of 2911.03%. This contributed to the annual value of -$83.8 million for FY2024, which is 3383.28% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Profit After Tax stood at -$26.8 million for Q3 2025, which was down 3847.94% from -$15.4 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Profit After Tax peaked at $133.3 million during Q4 2021, and registered a low of -$32.9 million during Q3 2022.
  • Moreover, its 5-year median value for Profit After Tax was -$17.9 million (2024), whereas its average is -$7.0 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first surged by 14756.35% in 2021, then plummeted by 77274.38% in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Profit After Tax (Quarter) stood at $133.3 million in 2021, then plummeted by 121.23% to -$28.3 million in 2022, then skyrocketed by 50.61% to -$14.0 million in 2023, then tumbled by 101.92% to -$28.2 million in 2024, then grew by 4.94% to -$26.8 million in 2025.
  • Its Profit After Tax was -$26.8 million in Q3 2025, compared to -$15.4 million in Q2 2025 and -$19.3 million in Q1 2025.